These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 877518)

  • 41. Plasma clearance rates of coagulation factors VIII and IX in factor-deficient individuals.
    Noe DA; Bell WR; Ness PM; Levin J
    Blood; 1986 Apr; 67(4):969-72. PubMed ID: 3082391
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Letter: Factor-VIII inhibitor bypassing activity.
    Pollock A; Lewis MJ
    Lancet; 1976 Jul; 2(7975):43-4. PubMed ID: 59103
    [No Abstract]   [Full Text] [Related]  

  • 43. Modification of the Bethesda assay for factor VIII or IX inhibitors to improve efficiency.
    Gadarowski JJ; Czapek EE; Ontiveros JD; Pedraza JL
    Acta Haematol; 1988; 80(3):134-8. PubMed ID: 3143212
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Orthotopic liver transplantation in a patient with combined hemophilia A and B.
    Delorme MA; Adams PC; Grant D; Ghent CN; Walker IR; Wall WJ
    Am J Hematol; 1990 Feb; 33(2):136-8. PubMed ID: 2105634
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative efficacy of nonheated and heat-treated factor IX complex concentrate in treatment of hemophiliacs with inhibitors.
    Schwartz RS; Ewing NP; Gorenc TJ; Spero JA
    Am J Hematol; 1989 Jan; 30(1):22-6. PubMed ID: 2491929
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Life-threatening sublingual hematoma in a severely hemophilic patient with factor VIII inhibitor.
    Takeuchi M; Shikimori M; Kaneda T
    J Oral Maxillofac Surg; 1986 May; 44(5):401-3. PubMed ID: 3084733
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factor VIII inhibitor by-passing activity (FEIBA) in the management of patients with factor VIII inhibitors.
    Preston FE; Dinsdale RC; Sutcliffe DJ; Bardhan G; Wyld PJ; Hamlyn JF
    Thromb Res; 1977 Nov; 11(5):643-51. PubMed ID: 929513
    [No Abstract]   [Full Text] [Related]  

  • 48. [Postpartum hemophilia A with factor VIII inhibitor].
    Neidhardt B; Bartels O; Hahn B
    Dtsch Med Wochenschr; 1985 May; 110(20):799-802. PubMed ID: 3922727
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of treatment with activated prothrombin complex concentrate (FEIBA) on factor VIII-antibody level.
    Lechner K; Nowotny C; Krinninger B; Zegner M; Deutsch E
    Thromb Haemost; 1979 Feb; 40(3):478-85. PubMed ID: 425062
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incidence of immune responses following 102 infusions of autoplex in 18 hemophilic patients with antibody to factor VIII.
    Laurian Y; Girma JP; Lambert T; Meyer D; Larrieu MJ
    Blood; 1984 Feb; 63(2):457-62. PubMed ID: 6419798
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].
    Shima M; Sawamoto Y; Kamisue M; Shibata Y; Tuzi S; Kuwabara M; Tanaka I; Tanizawa T; Tanaka A; Ueda M; Kakishita E; Yoshioka A
    Rinsho Ketsueki; 1996 Nov; 37(11):1303-8. PubMed ID: 8960666
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Home treatment in hemophilia].
    Pabinger I; Niessner H; Korninger C; Nowotny C; Stain M; Kyrle PA; Lechner K
    Wien Klin Wochenschr; 1987 Nov; 99(22):773-7. PubMed ID: 3124354
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Suppression of factor VIII inhibitor in children with hemophilia A].
    Zenz W; Muntean W
    Padiatr Padol; 1987; 22(4):345-52. PubMed ID: 3125510
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A five year experience of the use of factor IX type DE(I) concentrate for the treatment of Christmas disease of Oxford.
    Lane JL; Rizza CR; Snape TJ
    Br J Haematol; 1975 Aug; 30(4):435-46. PubMed ID: 1201227
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Disseminated intravascular coagulation after infusion of FEIBA (factor VIII inhibitor bypassing activity) in a patient with acquired haemophilia.
    Rodeghiero F; Castronovo S; Dini E
    Thromb Haemost; 1982 Dec; 48(3):339-40. PubMed ID: 6984544
    [No Abstract]   [Full Text] [Related]  

  • 56. Disseminated intravascular coagulation and infusion of factor-VIII-inhibitor bypassing activity.
    Stenbjerg S; Jorgensen J
    Lancet; 1977 Feb; 1(8007):360. PubMed ID: 64875
    [No Abstract]   [Full Text] [Related]  

  • 57. [Oral administration of factor VIII or IX concentrate preparation].
    Sakuragawa N
    Rinsho Ketsueki; 1985 Jul; 26(7):1086-9. PubMed ID: 3932721
    [No Abstract]   [Full Text] [Related]  

  • 58. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The use of continuous infusion of factor concentrates in the treatment of hemophilia.
    Bona RD; Weinstein RA; Weisman SJ; Bartolomeo A; Rickles FR
    Am J Hematol; 1989 Sep; 32(1):8-13. PubMed ID: 2502914
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Contact activation and factor VII after the use of an activated prothrombin complex concentrate (FEIBA) in hemophiliacs with inhibitors.
    Mariani G; Bouma BN; Mazzucconi MG; Avvisati G; Di Nucci GD; Corrao D; Mandelli F
    Thromb Res; 1983 Aug; 31(3):475-88. PubMed ID: 20218003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.